Elite in Essential Thrombocythemia

Dr. Ruben A. Mesa

The Charlotte-Mecklenburg Hospital Authority
Charlotte, NC
Elite
in Essential Thrombocythemia
Specialties:Hematology | Hematology Oncology | Oncology
Age:56
Accepting New Patients
Offers Telehealth
26 Years of Experience
OverviewInsuranceLocationsClinical Research

Overview

Ruben Mesa is a Hematologist and a Hematologist Oncology provider in Charlotte, North Carolina. Dr. Mesa has been practicing medicine for over 26 years and is rated as an Elite provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Bone Marrow Transplant, and Splenectomy. Dr. Mesa is currently accepting new patients.

His clinical research consists of co-authoring 396 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 52 articles and participated in 9 clinical trials in the study of Essential Thrombocythemia.

Specialties
Hematology
Hematology Oncology
Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Carolinas Medical Center/behav Health
North Carolina Baptist Hospital
Languages Spoken
English
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Medica
  •  Blue Cross Blue Shield
  •  AmeriHealth
  •  UnitedHealthcare
  •  Humana

Locations

THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY
1021 Morehead Medical Dr, Suite A, Charlotte, NC 28204
980-442-2000
Other Locations
WAKE FOREST UNIVERSITY HEALTH SCIENCES
Medical Ctr Blvd, Winston Salem, NC 27157
336-716-2734

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Ruxolitinib, Enasidenib
Study Phase: Phase 2
Phase II Study of P1101 in Early Myelofibrosis
Phase II Study of P1101 in Early Myelofibrosis
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Other, Biological
Study Drug: Ropeginterferon Alfa-2B
Study Phase: Phase 2
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
An Investigator Initiated Phase 2 Trial of the LSD1 Inhibitor IMG-7289 in Essential Thrombocythemia (CTMS# 19-0078)
An Investigator Initiated Phase 2 Trial of the LSD1 Inhibitor IMG-7289 in Essential Thrombocythemia (CTMS# 19-0078)
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: IMG-7289 LSD1 Inhibitor
Study Phase: Phase 2
A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea
A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Drug
Study Drugs: TGR-1202 PI3K Delta Inhibitor, Ruxolitinib
Study Phase: Phase 1
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
Enrollment Status: Active_not_recruiting
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drug: PEG-IFN-Alpha-2b
Study Phase: Phase 3
A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
Enrollment Status: Terminated
Publish Date: November 15, 2022
Intervention Type: Drug
Study Phase: Phase 1
Can a Mindfulness Meditation App Reduce Emotional Distress in Colorectal Cancer Patients Undergoing Adjuvant Chemotherapy
Can a Mindfulness Meditation App Reduce Emotional Distress in Colorectal Cancer Patients Undergoing Adjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: March 31, 2022
Intervention Type: Behavioral
Study Phase: Not Applicable
Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)
Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)
Enrollment Status: Completed
Publish Date: September 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Enrollment Status: Terminated
Publish Date: March 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML
Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML
Enrollment Status: Completed
Publish Date: February 28, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Enrollment Status: Completed
Publish Date: December 13, 2018
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Enrollment Status: Completed
Publish Date: January 11, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials

396 Total Publications

National Cancer Institute comprehensive cancer centers: Significant improvement in mortality and symptom control, further opportunities remain toward health equity.
National Cancer Institute comprehensive cancer centers: Significant improvement in mortality and symptom control, further opportunities remain toward health equity.
Journal: Cancer
Published: January 03, 2025
Similar Doctors
Expertise in
39
conditions
Dr. Ronald D. Butler
Oncology | Hematology
Expertise in
39
conditions
Dr. Ronald D. Butler
Oncology | Hematology
16455 Statesville Rd, Ste 280, 
Huntersville, NC 
 (16.1 mi)
980-442-4600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ronald Butler is an Oncologist and a Hematologist in Huntersville, North Carolina. Dr. Butler and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Thalassemia, Essential Thrombocythemia, Thrombocytopenia, and Small Cell Lung Cancer (SCLC). Dr. Butler is currently accepting new patients.

Expertise in
14
conditions
Dr. Kathryn F. Mileham
Oncology | Hematology | Hematology Oncology
Expertise in
14
conditions
Dr. Kathryn F. Mileham
Oncology | Hematology | Hematology Oncology

The Charlotte-Mecklenburg Hospital Authority

1021 Morehead Medical Dr, Suite A, 
Charlotte, NC 
980-442-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kathryn Mileham is an Oncologist and a Hematologist in Charlotte, North Carolina. Dr. Mileham and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Squamous Cell Lung Carcinoma. Dr. Mileham is currently accepting new patients.

Expertise in
42
conditions
Dr. Alaa A. Muslimani
Oncology | Hematology | Hematology Oncology
Expertise in
42
conditions
Dr. Alaa A. Muslimani
Oncology | Hematology | Hematology Oncology

The Charlotte-Mecklenburg Hospital Authority

1656 Riverchase Blvd, Suite 1400, 
Rock Hill, SC 
 (17.7 mi)
803-329-9088
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alaa Muslimani is an Oncologist and a Hematologist in Rock Hill, South Carolina. Dr. Muslimani and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Childhood Iron Deficiency Anemia, and Colorectal Cancer. Dr. Muslimani is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile